Politics

Tracking how politics and policy intersect with science and health care

Lamar Alexander
Politics

Sen. Lamar Alexander, a leading Republican on health legislation, will not seek reelection

By Nicholas Florko

BLT mouse
Politics

A guide to fetal tissue research: the controversy, the stakes, and the hunt for alternatives

By Ike Swetlitz

NIH
Politics

NIH report scrutinizes role of China in theft of U.S. scientific research

By Lev Facher

HHS Secretary Alex Azar
Politics

Top HHS official signals more interest in PhRMA’s limited plan for drug ads

By Ike Swetlitz

Gottlieb Generic Drugs
Politics

Gottlieb blasts high insulin prices, touts far-off new rules he says will spur competition in that market

By Nicholas Florko

New Opioid Approved - Dsuvia
The Pharmalot View

The military pushed it for the battlefield. The FDA went along. Is the newest opioid any better?

By Ed Silverman

Francis Collins
Politics

NIH to spend up to $20 million on search for alternatives to fetal tissue for research

By Ike Swetlitz

PhRMA & congress
Politics

The drug industry is headed back to Congress to make its case. Will Democrats keep the door open?

By Nicholas Florko

"beyond the diagnosis" 2016
Politics

After outcry, NIH apologizes for turning away portrait of person with rare disease

By Kate Sheridan

Politics

HIV research halted after NIH freezes acquisition of fetal tissue

By Kate Sheridan

Rep. Lloyd Doggett
Politics

Democrats are suddenly eyeing a valuable pharma asset: its patents

By Lev Facher

Donald Trump & Xi Jinping
Politics

The Trump administration called this biotech VC firm a suspicious agent of China. It’s run by U.S. citizens

By Rebecca Robbins

Charles Grassley
Politics

With new drug pricing legislation, Grassley and Wyden hint at the next steps for a powerful Senate committee

By Ike Swetlitz

Azar and Trump
Politics

The Trump administration has a new idea for changing drug rebates. That doesn’t mean it’s abandoning its earlier proposals

By Ike Swetlitz

The US Capitol
Politics

The new Congress is already threatening to push forward on drug pricing, but BIO CEO Jim Greenwood isn’t changing tack

By Nicholas Florko

STAT Plus November 29 Panel event
Politics

Watch: In a heated debate in Washington, key players spar over drug pricing policies

By Ike Swetlitz

Cassidy - STAT Plus November 29
Politics

Watch: Sen. Bill Cassidy weighs in on Trump’s drug pricing proposals and next year’s congressional agenda

By Nicholas Florko

Francis Collins
Politics

NIH director says there’s work to do on regulating genome editing globally

By Lev Facher

Sen. Bill Cassidy (R-LA)
Politics

Republican senator: pharma’s arguments against putting drug prices in TV ads are ‘patronizing’

By Elizabeth Cooney and Nicholas Florko

White pills on yellow background
Politics

A drug pricing duel: Tying U.S. drug prices to what other countries pay

By Elizabeth Cooney

Donald Trump speaks prior to signing bills intended to lower prescription drug prices
Politics

Trump administration takes aim at pharmacy fees in complicated new pitch for lowering drug costs

By Nicholas Florko

Alex Azar Part B
Politics

Trump administration proposes letting private Medicare plans exclude new types of drugs

By Nicholas Florko

Cobra
Politics

A SCOTUS case on ‘cobra sexual energy’ supplements highlights FDA’s oversight of a growing industry

By Nicholas Florko

Politics

What’s the fuss with Bernie Sanders’ new drug pricing bill?

By Nicholas Florko and Ike Swetlitz

iPhone
Politics

FDA proposes new regulations for some prescription drug-linked smartphone apps

By Kate Sheridan

Scott Gottlieb
Politics

Gottlieb pushes for funding to speed gene therapy reviews

By Ike Swetlitz

Brain neurons
Biotech

A pharma veteran best known for biotech reflects on leading a startup, pricing a drug, and investing in politics

By Adam Feuerstein, Damian Garde, and Rebecca Robbins

Patrick O'Connor
Politics

A newcomer rises to the defense of pharma — and tries to salvage its bruised reputation

By Ike Swetlitz

FDA Campus
Politics

FDA official hints at a tough road ahead for ‘right to try’

By Ike Swetlitz

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy